BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Religare maintains hold on Torrent Pharmaceuticals
Torrent Pharmaceuticals missed earnings estimates by 9-12 per cent due to weak domestic growth and price erosion in gAbility. US base business posted low double-digit growth despite price erosion of 5-7 per cent. However, Brazilian business rebounded strongly with 21 per cent growth.